Effects of L-Carnitine on Inflammatory Parameters and Angiogenesis in the Rat Air Pouch Model of Inflammation

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Pharmacology, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

2 Pharm D, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

3 Professor, Department of Pharmacology, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Background: In this study, effects of L-carnitine on inflammatory parameters and angiogenesis were evaluated in the rat air pouch model of inflammation.Methods: Male Wistar rats were anesthetized; 20 and 10 ml sterile air was injected subcutaneously on the back of rats at first and 3rd day. To induce inflammation, carrageenan 2% was injected intrapouch at 6th day. Saline as control and L-carnitine (250, 500, 1000 and 2000 µg/rat) were administrated intrapouch at the same time as the carrageenan injection, 24 and 48 hours after inflammation induction. After 72 hours, the pouches were opened and pouch fluids were collected to determine exudate volume, leukocyte counts, vascular endothelial growth factor (VEGF), and interleukin-1ß (IL-1ß) levels. The granulated tissue was dissected out and weighed. Angiogenesis in the granulation tissues was measured based on the hemoglobin concentration method.Findings: All used doses of L-carnitine reduced the leukocyte accumulation in the pouch fluid (P < 0.001); however, granulation tissue weight was decreased only by dose of 2000 µg (P < 0.001). In addition, L-carnitine significantly reduced volume of exudate in all treatment groups. Moreover, the agent produced inhibitory effect on IL-1ß level by doses of 250 and 500 µg. L-carnitine not only did not show an inhibitory effect on VEGF concentration, but also 1000 µg of L-carnitine increased VEGF level as compared to the control group (P < 0.010).Conclusion: Results of this study showed that the used doses of L-carnitine have anti-inflammatory effects without anti-angiogenesis activity in this model of inflammation. The anti-inflammatory effect of L-carnitine maybe related to its inhibitory effect on IL-1ß.

Keywords

References

  1. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010; 7: 30.
  2. Famularo G, De Simone C, Trinchieri V, Mosca L. Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation. Ann N Y Acad Sci 2004; 1033: 132-8.
  3. Shakeri A, Tabibi H, Hedayati M. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 2010; 14(4): 498-504.
  4. Lee BJ, Lin JS, Lin YC, Lin PT. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition 2015; 31(3): 475-9.
  5. Tastekin N, Aydogdu N, Dokmeci D, Usta U, Birtane M, Erbas H, et al. Protective effects of L-carnitine and alpha-lipoic acid in rats with adjuvant arthritis. Pharmacol Res 2007; 56(4): 303-10.
  6. Izgut-Uysal VN, Agac A, Derin N. Effect of L-carnitine on carrageenan-induced inflammation in aged rats. Gerontology 2003; 49(5): 287-92.
  7. Bishop-Bailey D, Bystrom J. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol Ther 2009; 124(2): 141-50.
  8. Khan FA, Khan MF. Inflammation and acute phase response. Int J Appl Biol Pharm 2017; 1(2): 312-21.
  9. Sharma RA, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep 2003; 10(5): 1625-31.
  10. Koch AE. Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 1998; 41(6): 951-62.
  11. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation 2003; 108(21): 2613-8.
  12. Martin SW, Stevens AJ, Brennan BS, Davies D, Rowland M, Houston JB. The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan. J Pharmacol Toxicol Methods 1994; 32(3): 139-47.
  13. Ghosh AK, Hirasawa N, Niki H, Ohuchi K. Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats. J Pharmacol Exp Ther 2000; 295(2): 802-9.
  14. Aldemir M, Pektas MB, Parlar AI, Akci O, Emren SV, Tecer E, et al. L-Carnitine Supplementation Reduces Short-Term Neutrophil-Lymphocyte Ratio in Patients Undergoing Coronary Artery Bypass Grafting. Int Surg 2015; 100(7-8): 1160-8.
  15. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins basic pathology. 8th ed. Philadelphia, PA: Saunders; 2007; p. 345-55.
  16. Abbas A, Lichtman AH, Pillai S. Cellular and molecular immunology. 7th ed. Philadelphia, PA: Saunders; 2011.
  17. Ruggiero V, D'Urso CM, Albertoni C, Campo S, Foresta P, Martelli EA. LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives. Mediators Inflamm 1993; 2(7): S43-S50.
  18. Morris CJ. Carrageenan-induced paw edema in the rat and mouse. In: Winyard PG, Willoughby DA, editors. Inflammation protocols. Totowa, NJ: Humana Press; 2003. p. 115-21.
  19. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT, et al. Nitric oxide: A key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 1996; 118(4): 829-38.
  20. Bueno R, Alvarez de Sotomayor M, Perez-Guerrero Cn, Gomez-Amores L, Vazquez CM, Herrera MD. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: Different participation of NO and COX-products. Life Sciences 2005; 77(17): 2082-97.
  21. Sato K, Komatsu N, Higashi N, Imai Y, Irimura T. Granulation tissue formation by nonspecific inflammatory agent occurs independently of macrophage galactose-type C-type lectin-1. Clin Immunol 2005; 115(1): 47-50.
  22. Amico-Roxas M, Caruso A, Cutuli VM, de BE, Leonardi G. Inhibitory effects of propionyl-L-carnitine on plasma extravasation induced by irritants in rodents. Drugs Exp Clin Res 1993; 19(5): 213-7.
  23. Sato IY, Kobayashi K, Yamagata N, Shikama Y, Kasama T, Kasahara K, et al. Modulation of granuloma formation in vitro by endogenous mediators. Immunopharmacology 1991; 21(2): 73-82.
  24. Iuvone T, Carnuccio R, Di Rosa M. Modulation of granuloma formation by endogenous nitric oxide. Eur J Pharmacol 1994; 265(1-2): 89-92.
  25. Koeck T, Kremser K. L-Carnitine alters nitric oxide synthase activity in fibroblasts depending on the peroxisomal status. Int J Biochem Cell Biol 2003; 35(2): 149-56.
  26. Salehi E, Amjadi FS, Khazaei M. Angiogenesis in health and disease: Role of vascular endothelial growth factor (VEGF). J Isfahan Med Sch 2011; 29(132): 312-26. [In Persian].
  27. De Angelis B, Gentile P, Orlandi F, Bocchini I, Di Pasquali C, Agovino A, et al. Limb rescue: A new autologous-peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers. Tissue Eng Part C Methods 2015; 21(5): 423-35.
  28. Cipolla MJ, Nicoloff A, Rebello T, Amato A, Porter JM. Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg 1999; 29(6): 1097-103.
Journal of Isfahan Medical School
Volume 35, Issue 437 - Serial Number 437
May and June 2017
Pages 807-813

Files

History

  • Receive Date: 16 April 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics